Wiggle Butt Academy Welcomes Rhea Northcut, CPDT-KA, CSAT, FDM — A Certified Expert in Separation Anxiety Training
Wiggle Butt Academy, a leader in science-based, positive reinforcement training, is proud to announce the addition of Rhea Northcut to the team.
'Separation Anxiety can be heartbreaking for both dogs and their humans. It's one of the leading causes of behavior-related surrender.'— Nicole Kohanski
TX, UNITED STATES, May 12, 2025 / EINPresswire.com / -- Wiggle Butt Academy, a leader in science-based, fear-free dog training in the DFW Metroplex, is proud to announce the addition of Rhea Northcut, CPDT-KA, CSAT, FDM to its expert team. Rhea joins Wiggle Butt Academy with over a decade of experience and a deep specialization in one of the most challenging behavior issues pet guardians face today: Separation Anxiety.
Rhea holds the prestigious Certified Separation Anxiety Trainer (CSAT) credential—an advanced certification achieved through a rigorous training program requiring hundreds of hours of instruction. She is one of two CSATs on the Wiggle Butt Academy team, joining fellow specialist Nicole Kohanski. Through a structured and evidence-based protocol, Rhea works virtually with clients across the globe to help dogs overcome the panic and distress caused by being left alone.
'Separation Anxiety can be heartbreaking for both dogs and their humans. It's one of the leading causes of behavior-related surrender,' says Nicole Kohanksi, Founder of Wiggle Butt Academy. 'Rhea's CSAT certification allows us to expand our reach and support families not just locally, but around the world.'
In addition to her CSAT designation, Rhea is also a Certified Professional Dog Trainer – Knowledge Assessed (CPDT-KA) and a Family Dog Mediator (FDM) through Kim Brophy's groundbreaking L.E.G.S. Applied Ethology model. She earned her Bachelor of Arts in Psychology from Texas Tech University, where she first discovered her passion for animal behavior. After initially pursuing a Master's in Counseling, Rhea shifted her focus to dog training full-time, recognizing her true calling was helping dogs—and their people—understand each other.
Rhea's training background spans shelter work, boarding facilities, private in-home lessons, sport and manners training, and remote coaching. Her approach blends academic knowledge, behavioral science, and heartfelt compassion. When not training, she enjoys time with her husband, daughters, and their Icelandic Sheepdog, Lizzie.
Rhea is now accepting virtual separation anxiety clients worldwide, as well as behavior and training clients virtually. To learn more about Wiggle Butt Academy's Separation Anxiety Program or to book a consultation with Rhea, visit www.wigglebuttacademy.com.
Nicole Kohanski, MBA, CTC, CDBC, CBCC-KA, CSAT
Wiggle Butt Academy LLC
+1 214-210-2695
email us here
Visit us on social media:
Instagram
Facebook
YouTube
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the best small company stocks to invest in. Stifel reaffirmed a Buy rating on Dianthus Therapeutics, Inc. (NASDAQ:DNTH) while maintaining a price target of $52.00, citing the strength of the company in keeping more cash than debt. This impressive upside of 186.3%, from the current price of $18.02, shows that the giant is heading north as it develops lead drug candidate DNTH103. The discussion revolved around the design of DNTH103 and its anticipated Phase 2 trial results for myasthenia gravis (MG), which is expected in September 2025. The management believes the success of DNTH103, relative to C5 inhibitors in the MG trial, would translate to the success of Dianthus Therapeutics, Inc. (NASDAQ:DNTH), driven by the drug's improved safety profile and straightforward dosing schedule through a biweekly autoinjector. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. Big changes are expected in the near future. The company is working to test DNTH103 in chronic inflammatory demyelinating polyneuropathy (CIDP), with interim results forecasted for the second quarter of 2026. If the MG trial goes well, this study will clear the path for a follow-up Biologics License Application. Dianthus Therapeutics, Inc. (NASDAQ:DNTH), founded in 2019, is a New York-based clinical-stage biotechnology company that develops complement therapeutics for patients living with autoimmune and inflammatory diseases. With a commitment to leverage selectivity in its treatments, the company is conducting clinical trials with DNTH103 in several indications. While we acknowledge the potential of DNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
New insight into Texas family detention reveals adults fighting kids for clean water
McALLEN, Texas (AP) — Adults fighting kids for clean water, despondent toddlers and a child with swollen feet denied a medical exam — these first-hand accounts from immigrant families at detention centers included in a motion filed by advocates Friday night are offering a glimpse of conditions at Texas facilities. Families shared their testimonies with immigrant advocates filing a lawsuit to prevent the Trump administration from terminating the Flores Settlement Agreement, a '90s-era policy that requires immigrant children detained in federal custody be held in safe and sanitary conditions. The agreement could challenge President Donald Trump's family detention provisions in his 'big, beautiful' bill of tax breaks and spending cuts, which also seeks to make the detention time indefinite and comes as the administration ramps up arrests. 'At a time when Congress is considering funding the indefinite detention of children and families, defending the Flores Settlement is more urgent than ever,' Mishan Wroe, a senior immigration attorney at the National Center for Youth Law, said in a statement Friday. Advocates with the center, as well as the Center for Human Rights and Constitutional Law, RAICES and Children's Rights contacted or visited children and their families held in two Texas family detention centers in Dilley and Karnes, which reopened earlier this year. The conditions of the family detention facilities were undisclosed until immigration attorneys filed an opposing motion before a California federal court. The oversight of the detention facilities was possible because of the settlement, and the visits help ensure standards compliance and transparency, said Sergio Perez, the executive director of the Center for Human Rights and Constitutional Law. Without the settlement, those overseeing the facilities would lose access to them and could not document what is happening inside. Out of 90 families who spoke to RAICES since March, 40 expressed medical concerns, according to the court documents. Several testimonies expressed concern over water quantity and quality. Emails seeking comment were sent to the Office of Attorney General Pam Bondi and to CoreCivic and Geo Group, which operate the detention facilities in Dilley and Karnes, Texas, respectively. There was no response from either Bondi's office or Geo Group by midday Saturday. CoreCivic referred questions to ICE. One mother was told she would have to use tap water for formula for her 9-month-old, who had diarrhea for three days after, and a 16-year-old girl described people scrambling over each other for water. 'We don't get enough water. They put out a little case of water, and everyone has to run for it," said the declaration from the girl held with her mother and two younger siblings at the Karnes County Immigration Processing Center. 'An adult here even pushed my little sister out of the way to get to the water first.' Faisal Al-Juburi, chief external affairs officer for RAICES, said Friday in a statement that the conditions 'only serve to reinforce the vital need for transparent and enforceable standards and accountability measures," citing an 'unconscionable obstruction of medical care for those with acute, chronic, and terminal illnesses.' One family with a young boy with cancer said he missed his doctor's appointment after the family was arrested following their attendance to an immigration court hearing. He is now experiencing relapse symptoms, according to the motion. Another family said their 9-month old lost over 8 pounds (3.6 kilograms) while in detention for a month. Children spoke openly about their trauma during visits with legal monitors, including a 12-year-old boy with a blood condition. He reported his feet became too inflamed to walk, and even though he saw a doctor, he was denied further testing. Now, he stays mostly off his feet. 'It hurts when I walk,' he said in a court declaration. Arrests have left psychological trauma. A mother of a 3-year-old boy who saw agents go inside his babysitter's home with guns started acting differently after detention. She said he now throws himself on the ground, bruises himself and refuses to eat most days. Growing concerns as ICE ramps up operations Many of the the families in detention were already living in the U.S. which reflects the recent shift from immigration arrests at the border to internal operations. Stephen Miller, White House deputy chief of staff and main architect of Trump's immigration policies, said U.S. Immigration and Customs Enforcement officers would target at least 3,000 arrests a day, up from about 650 a day during the first five months of Trump's second term. Leecia Welch, the deputy legal director at Children's Rights said that as bad as facility conditions are, they will only get worse as more immigrants are brought in. 'As of early June, the census at Dilley was around 300 and only two of its five areas were open," Welch said of her visits. "With a capacity of around 2,400, it's hard to imagine what it would be like with 2,000 more people.' Pediatricians like Dr. Marsha Griffin with the American Academy of Pediatrics Council said they are concerned and are advocating across the country to allow pediatric monitors with child welfare experts inside the facilities. Future of detention without Flores agreement The Flores agreement is poised to become more relevant if Trump's legislation called the ' One Big Beautiful Bill Act ' passes with the current language allowing the indefinite detention of immigrant families, which is not allowed under the Flores agreement. Trump's legislation approved by the House also proposes setting aside $45 billion in funding, a threefold spending increase, over the next four years to expand ICE detention of adults and families. The Senate is now considering that legislation. Under these increased efforts to add more detention space, GeoGroup, the same corporation operating the detention facility in Karnes, will soon be opening an infamous prison — which housed gangsters Al Capone and Machine Gun Kelly — for migrant detention in Leavenworth, Kansas. Immigration advocates argue that if the settlement were terminated, the government would need to create regulations that conform to the agreement's terms. 'Plaintiffs did not settle for policy making— they settled for rulemaking," the motion read. The federal government will have a chance to submit a reply brief. A court hearing is later scheduled for mid-July.
Yahoo
an hour ago
- Yahoo
GE HealthCare drives innovation in theranostics with latest technological advances
GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through a comprehensive portfolio of AI-powered imaging technologies, radiopharmaceuticals, cyclotrons, chemistry systems, and workflow-optimizing software—designed to support personalized, data-driven care across the entire patient journey. At #SNMMI25, the company is proud to introduce LesionID™ Pro with automated zero-click pre-processing,i which aims to help physicians minimize manual segmentation required to access patient-specific insights that can play a key role in delivering precision care with confidence. CHICAGO, June 21, 2025--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processingi – an AI-powered innovation to help aid physician decision making and therapy response monitoring. With cancer accounting for over 10 million deaths globally each year,ii the rise of precision care – particularly theranostics – is offering new hope to patients. By combining advanced diagnostic imaging and radiopharmaceuticals with targeted therapies, theranostics enables a personalized, patient-centric approach that may help improve disease detection, treatment accuracy, and overall quality of life. "Precision care is the future of oncology—and theranostics is at the heart of that future. The integration of advanced imaging and AI-powered software is accelerating the adoption of theranostics in clinical practice," shares Shyam Srinivas, MD, PhD, Chief of Nuclear Medicine, Associate Clinical Professor, Department of Radiological Sciences, University of California, Irvine. "With tools like GE HealthCare's Omni Legend, StarGuide, and MIM software at our disposal, we now have the ability to visualize disease with great clarity, quantify tumor burden efficiently, and make fast, informed decisions. These advancements are not only helping enhance diagnostic accuracy and therapy monitoring but are also opening the door to dosimetry—ultimately helping improve outcomes for our patients. This is precision care in action, and it's making a real difference in patients' lives." Central to the practice of theranostics is molecular imaging, such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), which provides detailed, patient-specific insights to guide and monitor treatment. However, accessing these insights – like whole-body tumor burden, which represents the total amount of cancer is in the body – has traditionally required time-consuming manual analysis, resulting in clinical and operational challenges. In response, GE HealthCare's MIM Software is introducing LesionID Pro with automated zero-click pre-processing,i designed with AI-powered automation to help physicians access reliable whole-body tumor burden statistics without having to spend hours manually segmenting lesions, removing normal physiologic uptake, and registering multiple patient images for comparison. In addition to turning manual pre-processing into a zero-click experience, this new version of LesionID Pro comes with significant algorithm improvements that provide physicians with a precise whole-body tumor volume to review and finalize. Intuitive, user-friendly tools were intentionally designed with input from leading theranostics practitioners with the ultimate goal of making whole-body tumor burden analysis a practical clinical reality and help shorten physicians' time-to-report. "At GE HealthCare, we are dedicated to providing clinicians the precision care tools needed for the adoption and practice of theranostics," shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. "We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient's entire care journey – from the imaging equipment needed for a noninvasive look at a patient's anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes." Also on display at #SNMMI25, as part of GE HealthCare's comprehensive portfolio of theranostics-enabling solutions for clinical and operational excellence, are the following innovations: MINItrace Magni,iii GE HealthCare's newest cyclotron technology, designed with a small footprint (about the size of a commercial refrigerator) and the goal of providing an easy-to-site, easy-to-install solution for the reliable, in-house production of commercial PET tracers and radiometals, including Gallium-68, used in diagnostic imaging to support personalized care plans. Adoption of such easy-to-site, easy-to-install technology may help enhance the capabilities of the healthcare system but also grant clinicians the ability to offer a variety of tracers to their patients and encourage the practice of precision care locally, helping fuel inhouse Theranostics capabilities. Omni Legend is a performance-focused PET/CT designed to evolve and help meet growing healthcare system demands by enabling clinicians to reduce dose by up to 40%iv while maintaining exceptional image quality. Supportive of the diagnostic portion of theranostics, the system continues to gain in popularity, representing the company's fastest-ever-selling PET/CT.v StarGuide is a digital SPECT/CT with a 12 CZT detector design that delivers high-quality 3D images and short scan times. Optimized for certain theranostic procedures, the system is designed to help clinicians pinpoint the size, shape, and position of lesions and monitor therapy with exceptional precision. Its flexibility in patient scanning and workflow efficiencies also support high patient throughput and help reduce complexity. For oncology patients, especially those in pain, short scans can help enhance comfort and overall experience. Aurora is an advanced dual-head SPECT/CT designed with excellent diagnostic capabilitiesvi and streamline workflows, offering clinicians excellent image quality and operational efficiency. Its CT has a 40 mm detector – twice the detector coverage compared to CTs of other hybrid systemsvii – with the ability to reduce the dose up to 82%,viii support accurate quantitation, and help clinicians make the personalized care decisions that are at the heart of theranostics. Theranostics Pathway Manager Tile is an easy-to-use application, available on GE HealthCare's Command Center software, that is designed to simplify the time-consuming task of coordinating the theranostics care pathway. It does so by tracking patient readiness for therapy, eliminating the need for manual data gathering across disparate systems (e.g., labs, scheduling, ordering, spreadsheets), and providing a unified, up-to-date view of each patient's treatment journey. Oregon Health & Science University will be an early adopter. "Every day counts when it comes to cancer care. The latest theranostics solutions will help our care teams more quickly and easily keep tabs on patient readiness and reduce patient coordination time—freeing up more time for clinicians to focus on direct patient care," says Erik Mittra, M.D., Ph.D., professor of diagnostic radiology in the at Oregon Health & Science University. Altogether, GE HealthCare has the unique ability to provide solutions along every step of the theranostics care pathway. Our integrated portfolio of solutions provides clinicians with the isotopes, imaging, informatics, and molecular imaging agents necessary for the practice and advancement of precision care. For more information on GE HealthCare's innovative portfolio of theranostics-enabling solutions, please visit SNMMI show attendees are also encouraged stop by the company's booth (#638 and #1023) at New Orleans Ernest N. Morial Convention Center in New Orleans, Louisiana from June 21-24. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™. Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website for more information. i LesionID Pro with automated zero-click pre-processing is 510(k)-pending with the U.S. FDA. Not CE Marked and not licensed in accordance with Canadian law. Not available for sale in the United States, Europe, Canada, or any other Cancer. World Health Organization. Published February 3, 2022. Accessed March 2, Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not CE Omni Legend 21cm as compared to Discovery MI Gen1 20cm. As demonstrated in phantom testing.v Based on orders data of GE HealthCare PET/CT systems since Compared to NM/CT 870 As compared to NM/CT 870 DR with Optima 540 a ASiR-V reduces dose by 50% to 82% relative to FBP at the same image quality (Image quality as defined by low contrast detectability).viii b In clinical practice, the use of ASiR‐V may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Low Contrast Detectability (LCD), Image Noise, Spatial Resolution and Artifact were assessed using reference factory protocols comparing ASiR‐V and FBP. The LCD was measured using 0.625 mm slices and tested for both head and body modes using the MITA CT IQ Phantom (CCT183, The Phantom Laboratory), using a model observer method. View source version on Contacts GE HealthCare Media Contact: Margaret SteinhafelM +1 608 381 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
